Not yet recruiting
TQB2922 Injection Given Under the Skin With Chemotherapy as Initial Treatment for Colorectal Cancer That Has Spread
NCT07844187· Phase 1/2· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source
Contact: Yanru Xie, Master's degree
Recruiting
A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07795346· Phase 3· Antengene Biologics Limited· Source
Contact: Yanru Xie
Recruiting
Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL-2)
NCT07800572· Phase 2· Capital Medical University· Source
Contact: Xunming Ji, PhD/MD
Not yet recruiting
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
NCT07691515· Phase 3· Zhejiang Cancer Hospital· Source
Contact: Jiansong Ji
Recruiting
Qishen Yiqi Dripping Pills in Treatment of Chronic Heart FailUre
NCT07687186· Phase 3· Tasly Pharmaceutical Group Co., Ltd· Source
Contact: Lingchun Lyu
Recruiting
Whole-life Investigation of Lishui Longevity
NCT07592962· The Fifth Affiliated Hospital of Wenzhou Medical University & Lishui Central Hospital· Source
Contact: Jingping Sun, PhD
Recruiting
Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke
NCT07509645· Phase 3· Capital Medical University· Source
Contact: Xiao Peng
Not yet recruiting
Ongericimab Injection Reducing Recurrence of Ischemic Stroke
NCT07242599· Phase 3· Beijing Tiantan Hospital· Source
Contact: Xiao Peng
Recruiting
MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
NCT07479485· Phase 1/2· Lepu Biopharma Co., Ltd.· Source
Contact: Jiansong Ji
Recruiting
Intra-arterial Thrombolysis for Acute Ischemic Stroke With Medium Vessel Occlusion
NCT07185022· The Second Hospital of Anhui Medical University· Source
Contact: Xiao Peng
Recruiting
Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)
NCT07265570· Phase 2· InSilico Medicine Hong Kong Limited· Source
Contact: Yang Deng
Active, not recruiting
Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke -2
NCT07263776· Phase 3· Capital Medical University· Source
Recruiting
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390· Phase 3· Eli Lilly and Company· Source
Contact: Lingchun Lv (principal investigator)
Recruiting
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
NCT07176650· Phase 1· Shanghai Henlius Biotech· Source
Contact: Henlius
Recruiting
Clinical Study of the Pulsed Electric Field Ablation System in Chronic Obstructive Pulmonary Disease
NCT07068438· Suzhou Hengruihongyuan Medical Technology Co. LTD· Source
Contact: Weiwen Li
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459· Phase 3· Amgen· Source
Not yet recruiting
Real-world Study on Liver Cancer Risk in Chronic Hepatitis B Patients With Family History of Liver Cancer
NCT07007286· Peking University First Hospital· Source
Contact: Jie Yang
Active, not recruiting
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
NCT06970743· Phase 3· BeOne Medicines· Source
Active, not recruiting
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
NCT06948435· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
NCT06948422· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
NCT06952530· Phase 3· Eli Lilly and Company· Source
Recruiting
A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.
NCT06844357· Phase 2/3· Zhejiang Raygene Pharmaceuticals Co., Ltd· Source
Contact: Jiansong Ji, M.D.
Recruiting
A Study on the Peripheral Blood in Patients With Acute Coronary Syndrome
NCT06955143· Second Affiliated Hospital of Wenzhou Medical University· Source
Contact: Jiayi Shen
Active, not recruiting
A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer
NCT07005336· Phase 2· TJ Biopharma Co., Ltd.· Source
Not yet recruiting
A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma
NCT06779461· Phase 3· InnoBM Pharmaceuticals Co., Ltd.· Source
Contact: Chuntao G PM
Recruiting
Efficacy and Safety of SR1375 in Adult Patients With CAP
NCT06577558· Phase 2· Shanghai SIMR Biotechnology Co., Ltd.· Source
Contact: Wang, PhD
Recruiting
Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients
NCT06520176· Phase 3· The Affiliated People's Hospital of Ningbo University· Source
Contact: Linjie Li
Recruiting
Clinical Trial Evaluating the Safety and Efficacy of Tumor Thermosensitive Embolic Agent in Transcatheter Arterial Chemoembolization for Primary Liver Cancer
NCT07356531· JIANGSU SHENMING Medical Technology CO., Ltd· Source
Contact: Jiansong Ji, chief physician
Recruiting
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
NCT06427941· Phase 1/2· BeOne Medicines· Source
Contact: Study Director
Active, not recruiting
SIM0718 Treatment of Asthma Clinical Study
NCT06488755· Phase 3· Simcere Pharmaceutical Co., Ltd· Source
Active, not recruiting
A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer
NCT06984588· Phase 2/3· TJ Biopharma Co., Ltd.· Source
Recruiting
Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)
NCT05872685· Phase 2· Yu jiren· Source
Contact: Hongtao Xu
Active, not recruiting
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
NCT05904886· Phase 3· Hoffmann-La Roche· Source
Not yet recruiting
Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
NCT05970627· Phase 2· Yu jiren· Source
Contact: Hongtao Xu
Recruiting
Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
NCT05729646· Phase 2· Yu jiren· Source
Contact: Hongtao Xu
Active, not recruiting
Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
NCT05715931· Phase 2· Yu jiren· Source
Recruiting
Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
NCT05652920· Phase 1/2· OriCell Therapeutics Co., Ltd.· Source
Contact: Jiansong Ji, MD
Active, not recruiting
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
NCT04662255· Phase 3· Loxo Oncology, Inc.· Source